AC Immune Outpaces Medical Peers with 2.2% YTD Return and 8% Earnings Estimate Upgrade
AC Immune’s stock has gained 2.2% year-to-date, outperforming the Medical sector’s –5.1% average and its Biomedical & Genetics industry peers’ 1.6% gain. Analysts have raised AC Immune’s full-year earnings estimate by 8% over the past three months, supporting its Zacks Rank #2 buy rating.
1. YTD Performance Outpacing Sector and Industry
Over the past three months AC Immune's stock has gained approximately 2.2% year-to-date, surpassing the Medical sector's average decline of 5.1% and outpacing its Biomedical & Genetics industry peers, which have averaged a 1.6% gain this year.
2. Earnings Estimate Revisions and Zacks Rank
Analysts have raised AC Immune's full-year earnings estimates by 8% over the past three months, reflecting improved sentiment around its pipeline progress and contributing to its Zacks Rank #2 (Buy), a rating reserved for stocks expected to outperform the market in the next one to three months.
3. Peer Comparison with Assertio in Medical Sector
Within the broader Medical sector, AC Immune's year-to-date return contrasts sharply with Assertio, which has delivered a 103% gain and a 110.7% increase in consensus EPS estimates, highlighting varying performance drivers across industry subgroups.